Updated Results from the Phase II Study of Blinatumomab in Combination with Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Rusfertide (Ptg-300) Treatment Interruption Reverses Hematological Gains and Upon Reinitiation, Restoration of Clinical Benefit Observed in Patients With Polycythemia Vera

Orca-T, A Precision Engineered Allograft, Results in High GVHD-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies

A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfi t/Frail Patients With Diffuse Large B-Cell Lymphoma (LOTIS-9)

AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation

Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study

First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study

The Impact of Post-Remission Granulocyte Colony-Stimulating Factor (G-CSF) Use (G-CSFu) in the Phase 3 Studies of Venetoclax (Ven) Combination Treatments in Patients (Pts) With Newly Diagnosed Acute Myeloid Leukemia (AML)

Magrolimab In Combination with Azacitidine for Patients with Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results

Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study

Community Versus Academic Practice in Essential Thrombocythemia and Myelofi brosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden: Analysis of Data from the MOST Study

Updated Progression-Free Survival and Depth of Response in IKEMA, a Randomized Phase 3 Trial of Isatuximab, Carfi lzomib, and Dexamethasone (Isa-Kd) Versus Kd in Relapsed Multiple Myeloma

Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3– Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)

BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofi brosis — JAK Inhibitor- Naïve or With Suboptimal Response to Ruxolitinib — Preliminary Data From the MANIFEST Study